-
Nature Sub-Journal: New Progress in the Research and Development of RAS Targeting Drugs
Time of Update: 2021-06-01
However, when the receptor tyrosine kinase is activated, RAS will switch from an inactive state combined with GDP to an activated state combined with GTP , So as to continuously activate the downstream signal pathway targets such as RAF, MEK and ERK, so that cells continue to proliferate, differentiate, and form tumors.
-
NAR: The new program may be able to identify thousands of cancer "weaknesses" from more than 700 different types of cancer cells
Time of Update: 2021-06-01
A few days ago, in a research report titled "SynLeGG: analysis and visualization of multiomics data for discovery of cancer'Achilles Heels' and gene function relationships" published in the international journal Nucleic Acids Research , scientists from Queen’s University and other institutions approved Analysis of more than 700 different types of cancer cells has identified the weaknesses of thousands of cancers, which may be expected to become a major feat in the history of cancer research.
-
The five-year survival rate is as high as 31.9%. Pembrolizumab makes it possible to cure advanced lung cancer
Time of Update: 2021-06-01
The study conducted parallel controlled trials on both K drug and chemotherapy regimens at the same time to compare the efficacy and safety of the two regimens in the first-line treatment of non-small cell lung cancer patients with PD-L1 TPS ≥50% and EGFR/ALK mutation negative.
-
JAMA: The incidence of colorectal cancer tends to be younger, and the starting age for screening has dropped to 45 years old
Time of Update: 2021-06-01
Recently, the US Preventive Services Task Force (USPSTF) released the latest colorectal cancer screening guidelines in JAMA.
The US Preventive Services Task Force (USPSTF) released the latest colorectal cancer screening guidelines in JAMA.
-
Br J Cancer: Phase II clinical study of pazopanib and topotecan in the treatment of patients with metastatic and unresectable soft tissue sarcoma
Time of Update: 2021-06-01
This prospective, single-arm, phase II study mainly evaluated the efficacy of pazopanib and topotecan in the treatment of patients with metastatic or unresectable non-lipocytoma STS.
This prospective, single-arm, phase II study mainly evaluated the efficacy of pazopanib and topotecan in the treatment of patients with metastatic or unresectable non-lipocytoma STS.
-
To overcome solid tumors, what challenges still need to be overcome in CAR-T therapy?
Time of Update: 2021-06-01
▲A variety of factors in the tumor microenvironment of solid tumors that may affect the efficacy of CAR-T cells (picture source: reference [1]) In order to overcome the impact of the tumor microenvironment, scientists have added a new generation of CAR-T therapies "Weapon" against immunosuppression.
-
Case case Shenghui | Unresectable locally advanced NSCLC adds a strong dose to the cornerstone of radiotherapy and chemotherapy
Time of Update: 2021-06-01
*This article is only used to provide scientific information to medical professionals, and does not represent the views of this platformEfficacy and safety of recombinant human endostatincombined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis[J].
-
Tilelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer|Tumor News
Time of Update: 2021-06-01
"Axitinib Tablets" Approved for Marketing JNCI: Relationship between Medicaid Expansion of Newly Diagnosed Young Cancer Patients and Cancer Stages and Differences 01JTO: Tilelizumab combined with chemotherapy can be used as locally advanced or metastatic non-squamous non First-line treatment options for small cell lung cancer A few days ago, JTO published a study online that tislelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
-
Harvard study: 30-year follow-up suggests that breast cancer patients will benefit significantly from drinking more coffee and tea!
Time of Update: 2021-06-01
This " health killer " who once took away the lives of Yao Beina, " Sister Lin " Chen Xiaoxu, Asang and others , is away from usFortunately, with the advancement of medical technology and the popularization of new breast cancer treatment strategies and methods, the survival rate of patients has been greatly improved.
-
Express | Early and more accurate diagnosis of prostate cancer metastasis or recurrence, FDA approves innovative imaging agent
Time of Update: 2021-06-01
Compared with traditional imaging detection, Pylarify PET imaging technology enables doctors to detect suspected metastatic or recurrent prostate cancer in any part of the body earlier and more accurately, so as to develop better treatment plans, which may have a huge impact on patients' lives .
-
Nat Commun: The immune evolution process from pre-tumor formation to invasive lung adenocarcinoma and its potential molecular characteristics
Time of Update: 2021-06-01
An in-depth understanding of the relevant molecular mechanisms of early lung cancer can speed up the precise diagnosis of the disease and the development of effective prevention and treatment strategies.
-
Nanda Sun Beicheng/Lin Anning research team collaborates to reveal a new regulatory mechanism for inflammation to promote liver cancer transformation
Time of Update: 2021-06-01
In this work, the research team proved that the abnormal activity of hepatocyte transcription factor NF-κB, whether it is missing or increased, can induce the inflammatory tumor microenvironment through different molecular mechanisms, thereby promoting the occurrence and development of liver cancer.
-
Br J Cancer: Cohort study of persistent neuropathy among early breast cancer survivors
Time of Update: 2021-06-01
The prognosis of patients with early breast cancer (ESBC) is good, but the risk of long-term adverse events must also be considered.
The prognosis of patients with early breast cancer (ESBC) is good, but the risk of long-term adverse events must also be considered.
-
"Early prevention, early intervention" for skin adverse reactions to maximize the benefits of anti-EGFR monoclonal antibody treatment-"Expert consensus on clinical management of skin adverse reactions related to anti-EGFR monoclonal antibody treatment" released
Time of Update: 2021-06-01
042) The "Consensus" is the first collaboration between nearly 30 experts from the two universities of oncology and dermatology in China in the field of colorectal cancer, combining the clinical evidence-based experience of tumor treatment and skin management , After repeated discussions after multiple rounds of review meetings, it summarized the mechanism, diagnosis and grading standards and prevention measures of adverse skin reactions caused by anti-EGFR monoclonal antibody drug treatments that have been approved for marketing in China.
-
Cell Death Differ: Bedaquiline targets ATP5F1C to prevent cancer cell metastasis
Time of Update: 2021-06-01
In this study, the researchers found that the high ATP production of mitochondrial ATP synthase is a new therapeutic target for anti-cancer therapy (especially the prevention of tumor development).
-
Professor Li Junjie: The results of the monarchE study on Asian populations are announced, and the intensive endocrine therapy for early breast cancer has added a new "edge"!
Time of Update: 2021-06-01
"The MonarchE study has confirmed the value of abesiride in the adjuvant treatment of early-stage high-risk breast cancer patients, but there are still many directions worth exploring in the future for enhanced adjuvant endocrine therapy.
-
Ann Hematol: Management of Adverse Events in the Maintenance Treatment of Isazomib after Multiple Myeloma Transplantation
Time of Update: 2021-06-01
The TOURMALINE-MM phase 3 study (NCT02181413) showed that after autologous stem cell transplantation (ASCT) in patients with multiple myeloma , maintenance therapy with ixazomib had an improved progression-free survival rate compared with placebo.
-
Case Sharing|Professor Zhang Ximei: Teriplimumab helps head and neck squamous cell carcinoma achieve complete remission
Time of Update: 2021-06-01
The postoperative pathology showed: (After laryngeal cancer, Left lobe of thyroid) squamous cell carcinoma, considered metastatic in combination with medical history, originated from the larynx; left deep lymph node of the neck (+) with vascular tumor thrombus; no cancer metastasis, soft tissue in the left central lymph node (+): 0/ 4.
-
Express | Breaking through the toxicity limit of immune combination therapy, the innovative CTLA-4 antibody/Keytruda clinical trial is about to start
Time of Update: 2021-06-01
(MSD) to evaluate its tumor-selective research anti-CTLA-4 monoclonal antibody XTX101, and Merck’s anti-PD-1 therapy Keytruda ( Pembrolizumab) combined with the safety and efficacy of the treatment of patients with solid tumors.
-
Six tumor vaccines and their advantages and disadvantages
Time of Update: 2021-06-01
Therefore, a large number of tumor antigens are presented in the immune system, and APCs such as DCs activate T cells to produce anti-tumor immunity.
DCs cells loaded with tumor antigens can directly activate T cells, cause cell activation, and produce anti-tumor immunity.
